Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
نویسندگان
چکیده
A controlled release preparation of levodopa-carbidopa, CR III, given every 4 hours to 17 Parkinsonian patients for up to 10 months reduced plasma drug variations and improved motor response fluctuations compared with standard levodopa-carbidopa given every 2 hours. The results support the value of pharmaceutical approaches to the stabilisation of circulating levodopa levels in the treatment of Parkinson's disease.
منابع مشابه
Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
Motor fluctuations complicate the treatment of patients with Parkinson's disease receiving levodopa. Extended-release carbidopa-levodopa has a pharmacokinetic profile that provides a more continuous levodopa serum concentration. Patients taking this formulation can expect longer duration of action and fewer doses per day, similar clinical improvement when compared to other levodopa formulations...
متن کاملThe catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
OBJECTIVES Entacapone is a specific, potent, peripherally acting catechol-O-methyltransferase (COMT) inhibitor. It has been shown to improve the bioavailability of plasma levodopa and extend its clinical effect when used as an adjunct to standard levodopa preparations, but there is little experience of the effect of entacapone on controlled release levodopa preparations. METHODS A double blin...
متن کاملNovel levodopa formulations in the treatment of Parkinson's disease.
Levodopa is the gold standard in Parkinson's disease (PD) treatment but its use is associated with motor complications. Levodopa pharmacokinetics, a short half-life, erratic gastric emptying and duodenal absorption, are key factors in their pathogenesis. As the disease progresses, frequency of levodopa administrations is increased leading to a complex treatment schedule and poor patient complia...
متن کاملLong-term efficacy of controlled-release carbidopa/levodopa in patients with advanced Parkinson's disease.
Twenty-one patients with Parkinson's disease and motor fluctuations who completed a double-blind study comparing controlled-release carbidopa/levodopa (Sinemet CR4) with standard Sinemet (SS) were evaluated one year following completion of the study. Five patients remained on CR4 alone; 16 continued on CR4 plus SS, and one also required addition of bromocriptine. Patients were significantly wor...
متن کاملPatient considerations in early management of Parkinson’s disease: focus on extended-release pramipexole
This article reviews the role of an extended-release formulation of pramipexole in the treatment of Parkinson's disease at an early stage. Pramipexole is a nonergot D(2)/D(3) synthetic aminobenzothiazole derivative that is effective as monotherapy in early disease and as an adjunct to levodopa in patients with motor fluctuations. Although levodopa is the current "gold standard" for treatment of...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Journal of neurology, neurosurgery, and psychiatry
دوره 50 2 شماره
صفحات -
تاریخ انتشار 1987